8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Nov 12, 2025·SEC
Caribou Biosciences, Inc.(CRBU)Earnings, Financials & Key Ratios
CRBU•NASDAQ
$1.88
$176M mkt cap·Price updated May 7, 2026
AboutCaribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.Show more
- Revenue$0-100.0%
- EBITDA-$148M+8.8%
- Net Income-$148M+0.7%
- EPS (Diluted)-1.59+3.6%
- ROE-78.97%-64.5%
- ROIC-55.6%-35.2%
- Debt/Equity0.22+112.8%
CRBU Key Insights
Caribou Biosciences, Inc. (CRBU) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CRBU Price & Volume
Caribou Biosciences, Inc. (CRBU) stock price & volume — 10-year historical chart
Loading chart...
CRBU Growth Metrics
Caribou Biosciences, Inc. (CRBU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-19%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-6.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-3.03%
Return on Capital
10 Years-52.61%
5 Years-41.29%
3 Years-49.36%
Last Year-68.58%
CRBU Recent Earnings
Caribou Biosciences, Inc. (CRBU) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Mar 5, 2026EPS
$0.28
Est $0.33
+15.2%
Revenue
$4M
Est $2M
+78.6%
Q4 2025
Nov 12, 2025EPS
$0.30
Est $0.36
+16.7%
Revenue
$2M
Est $2M
+12.3%
Q3 2025
Aug 12, 2025EPS
$0.35
Est $0.40
+12.5%
Revenue
$3M
Est $2M
+74.1%
Q2 2025
May 8, 2025EPS
$0.43
Est $0.43
+0.0%
Revenue
$2M
Est $2M
+27.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 5, 2026 | $0.28vs $0.33+15.2% | $4Mvs $2M+78.6% |
| Q4 2025 | Nov 12, 2025 | $0.30vs $0.36+16.7% | $2Mvs $2M+12.3% |
| Q3 2025 | Aug 12, 2025 | $0.35vs $0.40+12.5% | $3Mvs $2M+74.1% |
| Q2 2025 | May 8, 2025 | $0.43vs $0.43+0.0% | $2Mvs $2M+27.1% |
Based on last 12 quarters of dataView full earnings history →
CRBU Peer Comparison
Caribou Biosciences, Inc. (CRBU) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 | ||
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 ALLO | 520.77M | 2.27 | -2.61 | -100% | -57.07% | 0.26 | ||
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 | |
 TMO | 176.36B | 474.56 | 26.75 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare CRBU vs Peers
Caribou Biosciences, Inc. (CRBU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRBU Income Statement
Caribou Biosciences, Inc. (CRBU) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.79M | 12.36M | 9.6M | 13.85M | 34.48M | 9.99M | 0 | 9.29M |
| Revenue Growth % | - | 113.56% | -22.35% | 44.31% | 148.91% | -71.01% | -100% | -19% |
| Cost of Goods Sold | 0 | 34.42M | 984K | 3.64M | 3.52M | 3.93M | 0 | 30.5M |
| COGS % of Revenue | - | 278.5% | 10.25% | 26.29% | 10.22% | 39.29% | - | - |
| Gross Profit | 5.79M▲ 0% | -22.06M▼ 481.2% | 8.61M▲ 139.0% | 10.21M▲ 18.5% | 30.95M▲ 203.2% | 6.07M▼ 80.4% | 0▼ 100.0% | -21.2M▲ 0% |
| Gross Margin % | 100% | -178.5% | 89.75% | 73.71% | 89.78% | 60.71% | - | -228.08% |
| Gross Profit Growth % | - | -481.2% | 139.04% | 18.53% | 203.15% | -80.4% | -100% | - |
| Operating Expenses | 40.09M | 14.06M | 75.59M | 116.61M | 147.01M | 172.68M | 159.5M | 137.57M |
| OpEx % of Revenue | 692.69% | 113.74% | 787.59% | 841.88% | 426.4% | 1727.87% | - | - |
| Selling, General & Admin | 16.46M | 14.06M | 23.34M | 38.02M | 38.46M | 46.46M | 37.91M | 39.19M |
| SG&A % of Revenue | 284.35% | 113.74% | 243.15% | 274.49% | 111.56% | 464.85% | - | - |
| Research & Development | 23.64M | 34.42M | 52.26M | 82.23M | 112.08M | 130.15M | 109.44M | 116.09M |
| R&D % of Revenue | 408.34% | 278.5% | 544.44% | 593.68% | 325.07% | 1302.31% | - | - |
| Other Operating Expenses | 0 | -34.42M | 0 | -3.64M | -3.52M | -3.93M | 12.15M | 0 |
| Operating Income | -34.3M▲ 0% | -36.12M▼ 5.3% | -66.98M▼ 85.4% | -106.4M▼ 58.9% | -116.06M▼ 9.1% | -166.62M▼ 43.6% | -148.34M▲ 11.0% | -158.77M▲ 0% |
| Operating Margin % | -592.69% | -292.24% | -697.84% | -768.17% | -336.63% | -1667.16% | - | -1708.08% |
| Operating Income Growth % | - | -5.3% | -85.41% | -58.85% | -9.08% | -43.56% | 10.97% | - |
| EBITDA | -33.55M | -35.22M | -66M | -102.76M | -112.53M | -162.69M | -148.34M | -154.62M |
| EBITDA Margin % | -579.72% | -284.96% | -687.59% | -741.88% | -326.4% | -1627.87% | - | -1663.46% |
| EBITDA Growth % | - | -4.98% | -87.36% | -55.71% | -9.51% | -44.57% | 8.82% | 4.38% |
| D&A (Non-Cash Add-back) | 751K | 900K | 984K | 3.64M | 3.52M | 3.93M | 0 | 4.15M |
| EBIT | -30.96M | -36.11M | -66.59M | -99.35M | -116.06M | -166.62M | 0 | -144.16M |
| Net Interest Income | 1.04M | 216K | 140K | 4.6M | 10.7M | 0 | 0 | 0 |
| Interest Income | 1.05M | 236K | 148K | 4.6M | 10.7M | 0 | 0 | 0 |
| Interest Expense | 4K | 20K | 8K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3.34M | -3K | 377K | 7.05M | 14.18M | 17.5M | -331K | 1.63M |
| Pretax Income | -30.97M▲ 0% | -36.13M▼ 16.7% | -66.6M▼ 84.4% | -99.35M▼ 49.2% | -101.88M▼ 2.5% | -149.11M▼ 46.4% | -148.68M▲ 0.3% | -157.14M▲ 0% |
| Pretax Margin % | -535.04% | -292.27% | -693.92% | -717.28% | -295.49% | -1492.04% | - | -1690.54% |
| Income Tax | -7.54M | -1.82M | 321K | 70K | 193K | -9K | -550K | -9K |
| Effective Tax Rate % | 24.34% | 5.04% | -0.48% | -0.07% | -0.19% | 0.01% | 0.37% | 0.01% |
| Net Income | -23.43M▲ 0% | -34.31M▼ 46.4% | -66.92M▼ 95.1% | -99.42M▼ 48.6% | -102.07M▼ 2.7% | -149.1M▼ 46.1% | -148.13M▲ 0.7% | -157.13M▲ 0% |
| Net Margin % | -404.82% | -277.55% | -697.26% | -717.79% | -296.05% | -1491.95% | - | -1690.45% |
| Net Income Growth % | - | -46.42% | -95.07% | -48.56% | -2.66% | -46.08% | 0.66% | -6.08% |
| Net Income (Continuing) | -23.43M | -34.31M | -66.92M | -99.42M | -102.07M | -149.1M | -148.13M | -157.13M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.85▲ 0% | -1.24▼ 45.9% | -1.11▲ 10.5% | -1.64▼ 47.7% | -1.38▲ 15.9% | -1.65▼ 19.6% | -1.59▲ 3.6% | -1.68▲ 0% |
| EPS Growth % | - | -45.88% | 10.48% | -47.75% | 15.85% | -19.57% | 3.64% | -3.03% |
| EPS (Basic) | -0.85 | -1.24 | -1.11 | -1.64 | -1.38 | -1.65 | -1.59 | - |
| Diluted Shares Outstanding | 27.66M | 27.66M | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M | 93.29M |
| Basic Shares Outstanding | 27.66M | 27.66M | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M | 93.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
CRBU Balance Sheet
Caribou Biosciences, Inc. (CRBU) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 57.01M | 24.31M | 391.19M | 260.25M | 338.84M | 219.38M | 145.23M | 155.51M |
| Cash & Short-Term Investments | 49.47M | 15.95M | 375.83M | 247.66M | 328.83M | 209.54M | 139.34M | 147.26M |
| Cash Only | 41.07M | 15.95M | 240.42M | 58.34M | 51.16M | 16.29M | 12.36M | 11.14M |
| Short-Term Investments | 8.4M | 0 | 135.41M | 189.32M | 277.67M | 193.24M | 126.98M | 136.12M |
| Accounts Receivable | 3.98M | 5.16M | 8.12M | 4.66M | 3.86M | 3.25M | 1.97M | 2.07M |
| Days Sales Outstanding | 251.11 | 152.37 | 308.95 | 122.91 | 40.85 | 118.73 | - | 106.43 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 373K | 423K | 671K | 1.12M | 1.22M | 1.78M | 3.92M | 6.18M |
| Total Non-Current Assets | 4.92M | 11.74M | 51.16M | 113.52M | 93.37M | 93.94M | 30.14M | 39.48M |
| Property, Plant & Equipment | 4.33M | 3.5M | 4.89M | 34.91M | 40.45M | 39.29M | 24.43M | 23.6M |
| Fixed Asset Turnover | 1.34x | 3.53x | 1.96x | 0.40x | 0.85x | 0.25x | - | 0.30x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 7.63M | 45.3M | 77.07M | 51.33M | 49.13M | 0 | 62.65M |
| Other Non-Current Assets | 593K | 612K | 975K | 1.54M | 1.59M | 5.52M | 5.71M | 29.92M |
| Total Assets | 61.93M▲ 0% | 36.05M▼ 41.8% | 442.36M▲ 1127.2% | 373.76M▼ 15.5% | 432.21M▲ 15.6% | 313.31M▼ 27.5% | 175.37M▼ 44.0% | 194.98M▲ 0% |
| Asset Turnover | 0.09x | 0.34x | 0.02x | 0.04x | 0.08x | 0.03x | - | 0.04x |
| Asset Growth % | - | -41.8% | 1127.2% | -15.51% | 15.64% | -27.51% | -44.03% | -144.38% |
| Total Current Liabilities | 10.08M | 12.39M | 25.83M | 28.13M | 28.3M | 30.65M | 25.41M | 28.06M |
| Accounts Payable | 2.54M | 2.6M | 3.99M | 1.15M | 3.12M | 2.48M | 5.78M | 3.8M |
| Days Payables Outstanding | - | 27.58 | 1.48K | 114.88 | 323.06 | 230.13 | - | 40.08 |
| Short-Term Debt | 532K | 654K | 259K | 0 | 0 | 0 | 1.2M | 2.69M |
| Deferred Revenue (Current) | 717K | 161K | 8.7M | 9.94M | 2.85M | 3.13M | 1.9M | 11M |
| Other Current Liabilities | 496K | 629K | 4.75M | 7.12M | 10.62M | 10.22M | 22.32M | 19.35M |
| Current Ratio | 5.66x | 1.96x | 15.15x | 9.25x | 11.97x | 7.16x | 5.71x | 5.71x |
| Quick Ratio | 5.66x | 1.96x | 15.15x | 9.25x | 11.97x | 7.16x | 5.71x | 5.71x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | 66.34 |
| Total Non-Current Liabilities | 44.39M | 47.09M | 28.7M | 44.77M | 35.51M | 29.71M | 27.78M | 25.08M |
| Long-Term Debt | 0 | 924K | 0 | 0 | 0 | 0 | 26.03M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 26.78M | 25.91M | 25.06M | 0 | 95.72M |
| Deferred Tax Liabilities | 650K | 155K | 476K | 381K | 557K | 548K | 0 | 2.19M |
| Other Non-Current Liabilities | 42.76M | 45.08M | 6.19M | 1.65M | 2.94M | 785K | 1.75M | 1.24M |
| Total Liabilities | 54.47M | 59.48M | 54.53M | 72.89M | 63.81M | 60.36M | 53.19M | 53.14M |
| Total Debt | 532K | 1.58M | 259K | 27.75M | 27.11M | 26.49M | 27.23M | 25.46M |
| Net Debt | -40.54M | -14.38M | -240.42M | -30.59M | -24.05M | 10.19M | 14.87M | 14.32M |
| Debt / Equity | 0.07x | - | 0.00x | 0.09x | 0.07x | 0.10x | 0.22x | 0.22x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.16x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -0.09x |
| Interest Coverage | -8576.25x | -1806.20x | -8372.38x | - | - | - | - | - |
| Total Equity | 7.46M▲ 0% | -23.44M▼ 414.0% | 387.82M▲ 1754.8% | 300.87M▼ 22.4% | 368.4M▲ 22.4% | 252.95M▼ 31.3% | 122.17M▼ 51.7% | 141.84M▲ 0% |
| Equity Growth % | - | -414.04% | 1754.76% | -22.42% | 22.44% | -31.34% | -51.7% | -164.11% |
| Book Value per Share | 0.27 | -0.85 | 6.44 | 4.95 | 4.99 | 2.80 | 1.31 | 1.52 |
| Total Shareholders' Equity | 7.46M | -23.44M | 387.82M | 300.87M | 368.4M | 252.95M | 122.17M | 141.84M |
| Common Stock | 1K | 1K | 6K | 6K | 8K | 9K | 9K | 9K |
| Retained Earnings | 3.44M | -30.87M | -97.79M | -197.22M | -299.29M | -448.39M | -596.51M | -570.03M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -135K | -1.52M | 30K | 255K | 103K | 93K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRBU Cash Flow Statement
Caribou Biosciences, Inc. (CRBU) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -32.01M | -33.22M | -32.52M | -90.97M | -93.29M | -138.2M | -110.99M | -110.99M |
| Operating CF Margin % | -552.97% | -268.71% | -338.81% | -656.75% | -270.59% | -1382.83% | - | - |
| Operating CF Growth % | - | -3.78% | 2.1% | -179.73% | -2.56% | -48.14% | 19.69% | -27.72% |
| Net Income | -23.43M | -34.31M | -66.92M | -99.42M | -102.07M | -149.1M | -148.13M | -157.13M |
| Depreciation & Amortization | 751K | 900K | 984K | 3.64M | 3.52M | 3.93M | 3.65M | 4.15M |
| Stock-Based Compensation | 1.23M | 1M | 3.45M | 0 | 13.75M | 16.71M | 12.68M | 13.85M |
| Deferred Taxes | 0 | 0 | 0 | -95K | 0 | 0 | -548K | 0 |
| Other Non-Cash Items | -2.29M | -986K | 904K | 9.02M | -1.18M | -4.61M | 21.36M | 20.14M |
| Working Capital Changes | -8.27M | 177K | 29.07M | -4.11M | -7.32M | -5.11M | 0 | -6.65M |
| Change in Receivables | -1.09M | -1.18M | -2.96M | 3.46M | 805K | 608K | 196K | -266K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.18M | 43K | 1.14M | -2.72M | 1.82M | -354K | 3.25M | 1.11M |
| Cash from Investing | 27.23M | 6.36M | -176.4M | -93.25M | -68.18M | 86.61M | 102.24M | 100.2M |
| Capital Expenditures | -884K | -317K | -2.12M | -6.45M | -11.61M | -4.88M | -1.36M | -468K |
| CapEx % of Revenue | 15.27% | 2.56% | 22.1% | 46.6% | 33.68% | 48.83% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -988K | -1M | -600K | 0 | -1.61M | 1.14M | -1.61M |
| Cash from Financing | 172K | 1.74M | 433.43M | 2.13M | 154.3M | 16.72M | 4.82M | 4.61M |
| Debt Issued (Net) | -45K | 1.47M | 1.03M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 217K | 270K | 1000K | 1000K | 1000K | 1000K | 0 | 2.21M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 2.55M | 0 | 1.58M | 1.53M | 4.82M | 451K |
| Net Change in Cash | -4.6M▲ 0% | -25.12M▼ 445.9% | 224.51M▲ 993.9% | -182.08M▼ 181.1% | -7.18M▲ 96.1% | -34.87M▼ 385.9% | -3.93M▲ 88.7% | -20.83M▲ 0% |
| Free Cash Flow | -32.89M▲ 0% | -34.53M▼ 5.0% | -35.64M▼ 3.2% | -97.42M▼ 173.3% | -104.9M▼ 7.7% | -144.71M▼ 37.9% | -112.35M▲ 22.4% | -127.73M▲ 0% |
| FCF Margin % | -568.24% | -279.35% | -371.33% | -703.34% | -304.27% | -1447.92% | - | -1374.19% |
| FCF Growth % | - | -4.99% | -3.21% | -173.34% | -7.68% | -37.94% | 22.36% | 3.51% |
| FCF per Share | -1.19 | -1.25 | -0.59 | -1.60 | -1.42 | -1.60 | -1.20 | -1.20 |
| FCF Conversion (FCF/Net Income) | 1.37x | 0.97x | 0.49x | 0.91x | 0.91x | 0.93x | 0.75x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 1.81M | 21K | 11K | 0 | 170K | 0 | 0 | 0 |
CRBU Key Ratios
Caribou Biosciences, Inc. (CRBU) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -36.73% | -28.87% | -30.5% | -47.99% | -78.97% | -80.77% |
| Return on Invested Capital (ROIC) | - | -91.46% | -38.19% | -28.32% | -41.14% | -55.6% | -55.6% |
| Gross Margin | -178.5% | 89.75% | 73.71% | 89.78% | 60.71% | - | -228.08% |
| Net Margin | -277.55% | -697.26% | -717.79% | -296.05% | -1491.95% | - | -1690.45% |
| Debt / Equity | - | 0.00x | 0.09x | 0.07x | 0.10x | 0.22x | 0.22x |
| Interest Coverage | -1806.20x | -8372.38x | - | - | - | - | - |
| FCF Conversion | 0.97x | 0.49x | 0.91x | 0.91x | 0.93x | 0.75x | 0.81x |
| Revenue Growth | 113.56% | -22.35% | 44.31% | 148.91% | -71.01% | -100% | -19% |
CRBU SEC Filings & Documents
Caribou Biosciences, Inc. (CRBU) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRBU Frequently Asked Questions
Caribou Biosciences, Inc. (CRBU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Caribou Biosciences, Inc. (CRBU) reported $9.3M in revenue for fiscal year 2025. This represents a 61% increase from $5.8M in 2019.
Caribou Biosciences, Inc. (CRBU) saw revenue decline by 100.0% over the past year.
Caribou Biosciences, Inc. (CRBU) reported a net loss of $157.1M for fiscal year 2025.
Dividend & Returns
Caribou Biosciences, Inc. (CRBU) has a return on equity (ROE) of -79.0%. Negative ROE indicates the company is unprofitable.
Caribou Biosciences, Inc. (CRBU) had negative free cash flow of $127.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More CRBU
Caribou Biosciences, Inc. (CRBU) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates